Wang Chuan,Li Yanan,Xiang Bo,et al.Measuring reliability and validity of a Chinese mandarin version quality-of-life instrument for infantile hemangioma and its clinical application[J].Journal of Clinical Pediatric Surgery,,18():635-639,654.[doi:10.3969/j.issn.1671-6353.2019.08.004]
Measuring reliability and validity of a Chinese mandarin version quality-of-life instrument for infantile hemangioma and its clinical application
- Keywords:
- Hemangioma; Quality of Life; Infant
- CLC:
- R543;R732.2
- Abstract:
- Objective Infantile hemangioma (IH) is a common vascular tumor in children.Improving quality-of-life (QOL) in IH children and their family members is a vital target of therapy.The QOL instrument for IH is an IH-specific questionnaire,but its Chinese mandarin version has not been available yet.Thus a Chinese mandarin version QOL instrument for IH was developed for measuring its reliability and validity in Chinese populations.Methods The Chinese mandarin version QOL instrument for IH was administered to the parents of IH children.And Cronbach’s alpha coefficient was calculated.Multivariate linear regression analysis was used for determining the relevant influencing factors of QOL.Results A total of 201 IH children were recruited.The Cronbach’s alpha coefficient for the QOL instrument for IH summary scores was 0.766.The results demonstrated its excellent reliability and structural validity.Multivariate linear regression analysis revealed that two major influencing factors of QOL instrument for IH total scores were size and location of hemangioma.Conclusion The reliability and validity has been confirmed for the Chinese mandarin version of QOL instrument for IH.And hemangioma size and location are important influencing factors of QOL in children with IH and their parents.
References:
1 Frieden IJ,Eichenfield LF,Esterly NB,et al.Guidelines of care for hemangiomas of infancy.American Academy of Dermatology Guidelines/Outcomes Committee[J].J Am Acad Dermatol,1997,37(4):631-637.
2 Kilcline C,Frieden IJ.Infantile hemangiomas:How common are they? A systematic review of the medical literature[J].Pediatr Dermatol,2008,25(2):168-173.DOI:10.1111/j.1525-1470.2008.00626.x.
3 Hoornweg MJ,Smeulders MJ.Van der horst CM.Prevalence and characteristics of haemangiomas in young children[J].Ned Tijdschr Geneeskd,2005,149(44):2455-2458.
4 Munden A,Butschek R,Tom WL,et al.Prospective study of infantile haemangiomas:incidence,clinical characteristics and association with placental anomalies[J].B J Dermatol,2014,170(4):907-913.DOI:10.1111/bjd.12804.
5 Chamlin SL,Mancini AJ,Lai J,et al.Development and validation of a Quality-of-Life instrument for infantile hemangiomas[J].J Invest Dermatol,2015,135(6):1533-1539.DOI:10.1038/jid.2015.18.
6 Varni JW,Sherman SA,Burwinkle TM,et al.The PedsQL Family Impact Module:preliminary reliability and validity[J].Health Qual Life Outcomes,2004,2:55.DOI:10.1186/1477-7525-2-55.
7 Chen RQ,Hao YT,Feng LF,et al.The Chinese version of the Pediatric Quality of Life Inventory (TM) (PedsQL (TM)) Family Impact Module:cross-cultural adaptation and psychometric evaluation[J].Health Qual Life Outcomes,2011,910.DOI:10.1186/1477-7525-9-16.
8 Wang C,Li Y,Xiang B,et al.Quality of Life in children with infantile hemangioma:a case control study[J].Health Qual Life Outcomes,2017,15(1):10.DOI:10.1186/s12955-017-0772-z.
9 Wojcicki P,Wojcicka K.Epidemiology,diagnostics and treatment of vascular tumours and malformations[J].Adv Clin Exp Med,2014,23(3):475-484.DOI:10.17219/acem/37149.
10 祝秀丹,葛莉.心得安治疗婴儿血管瘤相关研究进展[J].临床小儿外科杂志,2012,11(06):475-476.DOI:10.3969/j.issn.1671-6353.2012.06.026.Zhu XD,Ge L.Update of research on infantile hemangiomas treated with propanolol[J].J Clin Ped Sur,2012,11(06):475-476.DOI:10.3969/j.issn.1671-6353.2012.06.026.
11 Leaute-Labreze C,Hoeger P,Mazereeuw-Hautier J,et al.A randomized,controlled trial of oral propranolol in infantile hemangioma[J].N Engl J Med,2015,372(8):735-746.DOI:10.1056/NEJMoa1404710.
12 Prey S,Voisard JJ,Delarue A,et al.Safety of propranolol therapy for severe infantile hemangioma[J].JAMA,2016,315(4):413-415.
13 Lawley LP,Siegfried E,Todd JL.Propranolol treatment for hemangioma of infancy:risks and recommendations[J].Pediatr Dermatol,2009,26(5):610-614.DOI:10.1111/j.1525-1470.2009.00975.x.
14 Janmohamed SR,Van Oosterhout M,De Laat PC,et al.Scoring the therapeutic effects of oral propranolol for infantile hemangioma:A prospective study comparing the Hemangioma Activity Score (HAS) with the Hemangioma Severity Scale (HSS)[J].J Am Acad Dermatol,2015,73(2):258-263.DOI:10.1016/j.jaad.2015.05.012.
15 Haggstrom AN,Beaumont JL,Lai J,et al.Measuring the severity of infantile hemangiomas instrument development and reliability[J].Arch Dermatol,2012,148(2):197-202.DOI:10.1001/archdermatol.2011.926.
16 Ji Y,Wang Q,Chen SY,et al.Oral atenolol therapy for proliferating infantile hemangioma A prospective study[J].Medicine (Baltimore),2016,95(24):554-560.DOI:10.1097/MD.0000000000003908.
17 Liu LS,Sokoloff D,Antaya RJ.Twenty-four-hour hospitalization for patients initiating systemic propranolol therapy for infantile hemangiomas-is it indicated?[J].Pediatr Dermatol,2013,30(5):554-560.DOI:10.1111/pde.12182.
18 Hoornweg MJ,Grootenhuis MA,van der Horst CM.Health-related quality of life and impact of haemangiomas on children and their parents[J].J Plast Reconstr Aesthet Surg,2009,62(10):1265-1271.DOI:10.1016/j.bjps.2008.03.021.
19 Zweegers J,van der Vleuten CJ.The psychosocial impact of an infantile haemangioma on children and their parents[J].Arch Dis Child,2012,97(10):922-926.DOI:10.1136/archdischild-2012-302470.
20 Bauland CG,Luning TH,Smit JM,et al.Untreated hemangiomas:growth pattern and residual lesions[J].Plast Reconstr Surg,2011,127(4):1643-1648.DOI:10.1097/PRS.0b013e318208d2ac.
21 Haggstrom AN,Drolet BA,Baselga E,et al.Prospective study of infantile hemangiomas:clinical characteristics predicting complications and treatment[J].Pediatrics,2006,118(3):882-887.DOI:10.1542/peds.2006-0413.
22 Xu GQ,Lv RR,Zhao ZF,et al.Topical propranolol for treatment of superficial infantile hemangiomas[J].J Am Acad Dermatol,2012,67(6):1210-1213.DOI:10.1016/j.jaad.2012.03.009.
23 Chan H,Mckay C,Adams S,et al.RCT of timolol maleate gel for superficial infantile hemangiomas in 5-to 24-Week-Olds[J].Pediatrics,2013,131(6):1739-1747.DOI:10.1542/peds.2012-3828.
24 Puttgen K,Lucky A,Adams D,et al.Topical timolol maleate treatment of infantile hemangiomas[J].Pediatrics,2016,138(3):e20160355.DOI:10.1542/peds.2016-0355.
Memo
收稿日期:2018-03-11。
基金项目:国家自然科学基金（编号：81401606）；四川大学优秀青年学者基金（编号：2015SU04A15）
通讯作者:吉毅,Email:jijiyuanyuan@163.com